company background image
EYPT

EyePoint Pharmaceuticals NasdaqGM:EYPT Stock Report

Last Price

US$7.75

Market Cap

US$263.9m

7D

6.9%

1Y

-12.1%

Updated

03 Jul, 2022

Data

Company Financials +
EYPT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

EYPT Stock Overview

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.

EyePoint Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for EyePoint Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.75
52 Week HighUS$21.50
52 Week LowUS$7.00
Beta1.17
1 Month Change-14.46%
3 Month Change-36.21%
1 Year Change-12.13%
3 Year Change-52.45%
5 Year Change-55.97%
Change since IPO-75.48%

Recent News & Updates

Shareholder Returns

EYPTUS PharmaceuticalsUS Market
7D6.9%-0.7%-2.5%
1Y-12.1%10.4%-21.2%

Return vs Industry: EYPT underperformed the US Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: EYPT exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is EYPT's price volatile compared to industry and market?
EYPT volatility
EYPT Average Weekly Movement9.3%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: EYPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: EYPT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987123Nancy Lurkerhttps://eyepointpharma.com

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

EyePoint Pharmaceuticals Fundamentals Summary

How do EyePoint Pharmaceuticals's earnings and revenue compare to its market cap?
EYPT fundamental statistics
Market CapUS$263.87m
Earnings (TTM)-US$67.11m
Revenue (TTM)US$38.91m

6.8x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EYPT income statement (TTM)
RevenueUS$38.91m
Cost of RevenueUS$41.53m
Gross Profit-US$2.62m
Other ExpensesUS$64.49m
Earnings-US$67.11m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.97
Gross Margin-6.73%
Net Profit Margin-172.48%
Debt/Equity Ratio23.7%

How did EYPT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is EYPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EYPT?

Other financial metrics that can be useful for relative valuation.

EYPT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA-1.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does EYPT's PS Ratio compare to its peers?

EYPT PS Ratio vs Peers
The above table shows the PS ratio for EYPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.2x
WVE Wave Life Sciences
6.5x68.6%US$275.8m
LQDA Liquidia
20.6x48.5%US$272.8m
OPTN OptiNose
3.9x26.1%US$301.0m
AERI Aerie Pharmaceuticals
2x20.3%US$406.5m
EYPT EyePoint Pharmaceuticals
6.8x31.3%US$263.9m

Price-To-Sales vs Peers: EYPT is good value based on its Price-To-Sales Ratio (6.8x) compared to the peer average (8.2x).


Price to Earnings Ratio vs Industry

How does EYPT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: EYPT is expensive based on its Price-To-Sales Ratio (6.8x) compared to the US Pharmaceuticals industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is EYPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EYPT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.8x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: EYPT is expensive based on its Price-To-Sales Ratio (6.8x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).


Share Price vs Fair Value

What is the Fair Price of EYPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EYPT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EYPT's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EYPT's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is EyePoint Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EYPT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EYPT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EYPT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EYPT's revenue (31.3% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: EYPT's revenue (31.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EYPT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has EyePoint Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-10.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: EYPT is currently unprofitable.

Growing Profit Margin: EYPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EYPT is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.

Accelerating Growth: Unable to compare EYPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EYPT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).


Return on Equity

High ROE: EYPT has a negative Return on Equity (-40.23%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is EyePoint Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: EYPT's short term assets ($219.6M) exceed its short term liabilities ($32.0M).

Long Term Liabilities: EYPT's short term assets ($219.6M) exceed its long term liabilities ($45.8M).


Debt to Equity History and Analysis

Debt Level: EYPT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if EYPT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EYPT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EYPT has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 13.6% each year.


Discover healthy companies

Dividend

What is EyePoint Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate EYPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EYPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EYPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EYPT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EYPT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Nancy Lurker (65 yo)

5.83yrs

Tenure

US$3,623,368

Compensation

Ms. Nancy S. Lurker serves as a Member of Advisory Group at Novo Holdings A/S. She has been the Chief Executive Officer and President of EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.) sin...


CEO Compensation Analysis

Compensation vs Market: Nancy's total compensation ($USD3.62M) is above average for companies of similar size in the US market ($USD1.83M).

Compensation vs Earnings: Nancy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: EYPT's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: EYPT's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.5%.


Top Shareholders

Company Information

EyePoint Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: EyePoint Pharmaceuticals, Inc.
  • Ticker: EYPT
  • Exchange: NasdaqGM
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$263.865m
  • Shares outstanding: 34.05m
  • Website: https://eyepointpharma.com

Number of Employees


Location

  • EyePoint Pharmaceuticals, Inc.
  • 480 Pleasant Street
  • Suite B300
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.